The neuroleptic malignant syndrome: agent and host interaction

Acta Psychiatr Scand. 1986 Apr;73(4):337-47. doi: 10.1111/j.1600-0447.1986.tb02694.x.

Abstract

This review comprises an exhaustive analysis of 120 case reports of neuroleptic malignant syndrome (NMS) representing the majority of published clinical data on this syndrome. Epidemiological, clinical and biological parameters, as well as those concerning the agent and the treatment of the syndrome, are critically evaluated on the basis of this data. The rate of neuroleptic loading is shown to play a cardinal role in the development of NMS. Rechallenge and aftercare of patients who need anti-psychotic treatment after NMS are considered.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Aftercare
  • Aged
  • Akathisia, Drug-Induced
  • Amantadine / therapeutic use
  • Antiparkinson Agents / therapeutic use
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / adverse effects*
  • Benzodiazepines / therapeutic use
  • Bromocriptine / therapeutic use
  • Carbidopa / therapeutic use
  • Child
  • Child, Preschool
  • Dantrolene / therapeutic use
  • Dose-Response Relationship, Drug
  • Electroconvulsive Therapy
  • Female
  • Haloperidol / adverse effects
  • Humans
  • Leukocytosis / chemically induced
  • Male
  • Middle Aged
  • Neuroleptic Malignant Syndrome / drug therapy
  • Neuroleptic Malignant Syndrome / etiology*

Substances

  • Antiparkinson Agents
  • Antipsychotic Agents
  • Benzodiazepines
  • Bromocriptine
  • Amantadine
  • Dantrolene
  • Haloperidol
  • Carbidopa